Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

@article{Bono2010PrednisonePC,
  title={Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial},
  author={Johann Sebastian de Bono and St{\'e}phane Oudard and Mustafa Ozguroglu and Steinbj{\o}rn Hansen and Jean-Pascal H Machiels and Ivo Koc{\'a}k and Gwena{\"e}lle Gravis and Istv{\'a}n Bodrogi and Mary J. Mackenzie and Liji Shen and Martin Roessner and Sunil Gupta and A. Oliver Sartor},
  journal={The Lancet},
  year={2010},
  volume={376},
  pages={1147-1154}
}

Figures and Tables from this paper

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

Cabazitaxel should be considered the preferred treatment option over abiraterone or enzalutamide in the metastatic castration-resistant prostate cancer setting and are reflective of the Japanese patient population.

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Second-line AAP for patients with mCRPC is the most common treatment strategy after progression with a docetaxel-based regimen, and when controlling for potential confounders, patients receiving this treatment showed no differences in PFS and OS in comparison to those receiving CP, although these latter results should be confirmed in randomized controlled trials.
...

References

SHOWING 1-10 OF 20 REFERENCES

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  • I. TannockD. Osoba K. Murphy
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
Chemotherapy with mitoxantrone and prednisone provides palliation for some patients with symptomatic hormone-resistant prostate cancer and most responding patients had an improvement in quality-of-life scales and a decrease in serum prostate-specific antigen (PSA) level.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.

XRP6258 was active and well tolerated in this group of MBC patients with taxane-resistant disease, and these results support the further clinical development of this agent.

Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.

DE had superior clinical efficacy with similar global quality of life and pain palliation in the MP arm with a consistent lack of statistically significant global QOL differences for the two arms.

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

The general tolerability and encouraging antitumor activity in taxane-refractory patients warrant further evaluations of XRP6258.

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  • H. ScherS. Halabi M. Hussain
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.

It is suggested that the appropriate control arm for phase III testing in endocrine-resistant patients continues to be a no chemotherapy control arm consisting of a best symptomatic care or a uniformly applied second-line endocrine manipulation.

Update on tubulin-binding agents.